Cytek Biosciences, Inc. (CTKB) Misses Q4 EPS by 2c

Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q4 EPS of $0.02, $0.02 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $164.04 million versus the consensus estimate of $50.22 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist